Michael Snitkovsky is a global biopharma operations leader with more than 20 years of
experience advancing therapies from preclinical research through clinical development and
toward commercialization. He has led major multinational collaborations, including a $70M
strategic partnership, and managed alliances across the U.S., Europe, China, and Japan. His
work spans oncology, immunology, IBD, rare diseases, and neurological and psychiatric
conditions, including clinical programs in MDD and bipolar depression. He has a proven
track record of guiding numerous IND, CTA, BLA, and NDA submissions across global
regulatory agencies. Michael’s expertise includes CMC strategy, regulatory program
management, and COO‑level operational leadership in high‑growth biotech settings. He is
known for his strategic clarity, operational discipline, and ability to align global teams
around shared scientific and organizational goals.